CD274 and neoplasm: Therapies aimed at modulating the tumor-immune cell dialogue, by using for example immune checkpoint inhibitors such as the anti-programmed cell death ligand 1 (PD-L1 or CD274) or anti-PD1 [46], with PD-L1 also detected among the SKBR3 membrane proteins, are expected to find a fertile ground in the rich backdrop of cell-membrane antigens.